Retatrutide: What the Research Actually Shows
Last updated: March 25, 2026
Retatrutide (LY3437943) produced an average 24.2% body weight loss at 48 weeks in the landmark Phase 2 trial published in the New England Journal of Medicine — the highest weight loss recorded for any anti-obesity drug in a clinical trial to date. It works by simultaneously activating three metabolic receptors: GLP-1, GIP, and glucagon.
(12mg, 48 weeks)
(GIP + GLP-1 + Glucagon)
📋 On this page
- A Triple Receptor Agonist
- Weight Loss by Dose
- Who Actually Loses Weight?
- How Does It Compare?
- Side Effects Breakdown
- Trial Details
- Phase 3 Data: The Numbers Get Even Better
- Who Researches Retatrutide?
- What the Data Actually Tells Us
- Related Resources
- Related Research Guides
- 🛒 Essential Supplies
- What to Expect: A Patient Timeline
- 🔗 Related Resources
Mechanism of Action
A Triple Receptor Agonist
Retatrutide (LY3437943) simultaneously activates three metabolic receptors — a combination no approved drug achieves. Here's what each target does.
GLP-1 Receptor
Controls appetite, slows gastric emptying, and enhances insulin secretion in response to meals. This is the same target as semaglutide (Ozempic/Wegovy) — a proven weight-loss mechanism in hundreds of thousands of patients.
GIP Receptor
Boosts insulin sensitivity and enhances fat metabolism. This is the same second target added by tirzepatide (Mounjaro/Zepbound), which is responsible for its superior efficacy over earlier GLP-1-only drugs.
Glucagon Receptor
The breakthrough third target. Activating glucagon receptors increases energy expenditure, promotes direct fat burning, and enhances hepatic (liver) metabolism. Only retatrutide hits this target — and it may explain the superior weight loss numbers.
Phase 2 Trial Data
Weight Loss by Dose
Average percent body weight lost across all dose groups, measured at 24 and 48 weeks. Bars animate when you scroll to this section.
48-Week Outcomes
Who Actually Loses Weight?
Percentage of participants achieving meaningful weight loss thresholds at 48 weeks. The higher the dose, the more consistent the results.
Competitive Landscape
How Does It Compare?
Retatrutide vs the two leading approved GLP-1 medications. These are cross-trial estimates — see the note below.
(GIP + GLP-1 + GCG)
(48 weeks)
(GIP + GLP-1)
(72 weeks, SURMOUNT-1)
(GLP-1 only)
(68 weeks, STEP 1)
Safety Profile
Side Effects Breakdown
Reported adverse events for the 12mg dose group. Rates are consistent with the broader GLP-1 drug class — mostly GI-related and dose-dependent.
💡 Titration Matters
Starting at 2mg and slowly titrating up to higher doses significantly reduced GI side effects compared to starting directly at 4mg. Slow escalation is the standard protocol in clinical practice for all GLP-1-class drugs.
📊 Context on These Numbers
Most GI side effects were mild to moderate in severity and resolved over time. The discontinuation rate due to adverse events was low and consistent with other drugs in this class. No new serious safety signals were identified in the 48-week trial period.
⚗️ 12mg Dose Data
All side effect percentages shown here are for the highest-dose group (12mg) where GI effects are most pronounced. Lower doses (4mg, 8mg) showed meaningfully lower rates of nausea and vomiting while still delivering strong efficacy.
Study Metadata
Trial Details
All data on this page is sourced from the Phase 2 NEJM publication. Full citation below.
Phase 2 Randomized Controlled Trial
Retatrutide (LY3437943) for Obesity — Full Study Record
Phase 3 Update — December 2025
Phase 3 Data: The Numbers Get Even Better
The Phase 2 NEJM data was already historic. Then Phase 3 reported — and retatrutide may be setting records that won't be broken for a long time.
⚖️ Phase 3 Weight Loss Data (Dec 2025)
Placebo-adjusted weight loss hit 26.6%. The trial enrolled people with obesity plus knee osteoarthritis — a harder-to-treat population than the typical obesity trial. These may be the highest weight-loss numbers ever reported in a late-stage pharmaceutical trial for any indication.
🦵 Bonus Finding: Knee Pain −75%
The Phase 3 trial specifically enrolled patients with both obesity and knee osteoarthritis. In addition to exceptional weight loss, participants reported a 75% reduction in knee pain — a result driven both by reduced joint loading and direct anti-inflammatory effects.
This positions retatrutide as potentially relevant well beyond obesity — it could become a treatment of choice for the large overlap population with obesity-driven osteoarthritis.
🫀 Phase 2 Liver Substudy: Cardiometabolic Profile
A liver-focused substudy within the Phase 2 program examined retatrutide's effects on liver fat and cardiometabolic markers. The glucagon component is believed to drive direct hepatic fat oxidation — and the results reflect this.
(higher doses)
reduced
range
Placebo comparison for liver fat: the placebo group saw a 0.3% increase in liver fat over the same period — making the contrast even more striking.
Self-Assessment
Who Researches Retatrutide?
This Research Is Commonly Explored By People Who...
- Are interested in the next generation of multi-receptor agonists (GLP-1/GIP/glucagon triple agonist)
- Want to understand Phase 2 data showing up to 24% weight loss at 48 weeks
- Have followed GLP-1 research and want to track emerging therapies in the pipeline
- Are curious about glucagon receptor activation and its role in energy expenditure
- Want to compare retatrutide's early data against approved options like semaglutide and tirzepatide
This Research May Not Be Relevant If...
- You want something available now — retatrutide is still in Phase 3 clinical trials (not FDA approved)
- You prefer established safety profiles — long-term data is still being collected
- You need a treatment plan today — discuss approved options with your healthcare provider first
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Bottom Line
What the Data Actually Tells Us
Separating confirmed Phase 2 findings from what still needs to be established in Phase 3 trials.
- Retatrutide achieved the highest average weight loss of any obesity medication tested in a clinical trial
- 100% of participants on 8mg and 12mg doses lost at least 5% of body weight — a clinically meaningful threshold
- The triple agonist mechanism (adding glucagon receptor activation) appears to offer genuinely superior results compared to dual-agonist drugs
- Side effects are manageable and mostly GI-related, consistent with the broader drug class — slow titration reduces incidence
- Weight loss continued to increase from 24 to 48 weeks, suggesting the drug had not yet hit a plateau at study end
- Phase 3 trials are ongoing — larger scale data across more diverse populations is still needed before FDA review
- Long-term safety beyond 48 weeks has not yet been established in published data
- No published head-to-head trials against tirzepatide or semaglutide exist — cross-trial comparisons have real limitations
- FDA approval timeline remains uncertain; current estimates suggest 2026–2027 at the earliest pending Phase 3 readouts
- Real-world effectiveness may differ from the highly controlled clinical trial setting (adherence, diet, comorbidities)
Continue Reading
Related Resources
Calculators, vendor guides, and dosing information for weight loss peptides.
More Research
Related Research Guides
🛒 Essential Supplies
Everything you need for peptide preparation and administration
Affiliate links help support HighPeptides at no extra cost to you.
What to Expect: A Patient Timeline
Based on the retatrutide Phase 2 trial (NEJM 2023, NCT04881760, n=338) at the highest dose (12 mg/week). Lower doses produce proportionally smaller effects. Individual results vary significantly.
Triple Receptor Activation & Rapid Appetite Suppression
Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors — a triple mechanism that distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1). GLP-1 activity suppresses appetite, GIP enhances the GLP-1 response, and glucagon receptor activation increases energy expenditure and thermogenesis. Phase 2 participants experienced strong early satiety signals within days. Nausea and GI discomfort are common early on due to accelerated dose escalation in the trial protocol.
Rapid Early Weight Loss
The glucagon receptor component of retatrutide drives higher energy expenditure compared to GLP-1-only drugs — participants burn more calories even at rest. Phase 2 data shows early weight loss trajectories steeper than observed with semaglutide or tirzepatide at equivalent timepoints. Food intake reduction is profound, with many participants describing dramatic changes in hunger and portion size within the first month.
Significant Weight Loss & Metabolic Changes
By week 12–24, retatrutide participants in the Phase 2 trial showed approximately 12–17% body weight loss (12 mg group), outpacing semaglutide at the same timepoints. Fasting insulin, triglycerides, and waist circumference all improve significantly. Lean mass preservation is a key differentiator — glucagon receptor agonism promotes fat oxidation while sparing muscle. GI side effects become less frequent as the dose stabilizes.
Record-Setting Weight Loss & Body Composition Changes
The Phase 2 trial showed 24.2% average body weight loss at 48 weeks in the highest-dose group (12 mg) — a result unprecedented in clinical trials for a pharmacological agent at that time. All dose groups showed statistically significant improvements in waist circumference, systolic blood pressure, fasting glucose, and lipid panels. Visceral (abdominal) fat — the metabolically dangerous type — showed particularly strong reductions. Phase 3 trials (TRIUMPH program) are ongoing to confirm these results in larger populations.
Weight Loss Improves Sleep — But Watch for GLP-1 Nausea at Night
The weight loss driven by GLP-1/GIP/glucagon tri-agonists like retatrutide has a well-documented benefit: obesity-related sleep apnea often resolves as BMI falls. Trial data shows significant reductions in AHI (apnea-hypopnea index) correlating with weight loss magnitude. This is an underappreciated downstream benefit.
However, GLP-1 nausea — most common in the titration phase — can disrupt sleep when dosing is timed too close to bedtime. Most protocols recommend injecting in the morning or at least 4–6 hours before sleep. Poor sleep in turn elevates ghrelin and impairs the appetite suppression you're relying on.
→ Sleep Optimization for GLP-1 UsersResearch-Grade Retatrutide
The triple-agonist (GLP-1/GIP/glucagon) currently in Phase 3 trials. Research-grade with COA.
Browse Retatrutide at Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide is an investigational drug not yet approved by the FDA for any indication. Always consult with a qualified healthcare provider before starting any medication or treatment protocol. Data sourced from published peer-reviewed research (NEJM 2023, NCT04881760).